SciClone Pharmaceuticals Stock Price, News & Analysis (NASDAQ:SCLN)

$11.15 0.00 (0.00 %)
(As of 02/25/2018 04:00 PM ET)
Previous Close$11.15
Today's RangeN/A
52-Week Range$8.55 - $11.43
VolumeN/A
Average VolumeN/A
Market Capitalization$581.94 million
P/E Ratio12.97
Dividend YieldN/A
BetaN/A

About SciClone Pharmaceuticals (NASDAQ:SCLN)

SciClone Pharmaceuticals logoSciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company's business is focused primarily in the People's Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL). Its development portfolio includes Angiomax, Loramyc, Neucardin, VIBATIV and Cleviprex.

Receive SCLN News and Ratings via Email

Sign-up to receive the latest news and ratings for SCLN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNASDAQ:SCLN
CUSIP80862K10
Phone+1-650-3583456

Debt

Debt-to-Equity RatioN/A
Current Ratio8.36%
Quick Ratio7.57%

Price-To-Earnings

Trailing P/E Ratio12.9651162790698
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS$0.86
Net IncomeN/A
Net Margins27.39%
Return on Equity20.24%
Return on Assets18.42%

Miscellaneous

Employees570
Outstanding Shares52,190,000

SciClone Pharmaceuticals (NASDAQ:SCLN) Frequently Asked Questions

What is SciClone Pharmaceuticals' stock symbol?

SciClone Pharmaceuticals trades on the NASDAQ under the ticker symbol "SCLN."

How were SciClone Pharmaceuticals' earnings last quarter?

SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) released its quarterly earnings results on Tuesday, May, 10th. The specialty pharmaceutical company reported $0.19 earnings per share for the quarter. The specialty pharmaceutical company had revenue of $36.50 million for the quarter, compared to analysts' expectations of $33.60 million. SciClone Pharmaceuticals had a net margin of 27.39% and a return on equity of 20.24%. View SciClone Pharmaceuticals' Earnings History.

Where is SciClone Pharmaceuticals' stock going? Where will SciClone Pharmaceuticals' stock price be in 2018?

1 Wall Street analysts have issued twelve-month price targets for SciClone Pharmaceuticals' stock. Their forecasts range from $14.00 to $14.00. On average, they anticipate SciClone Pharmaceuticals' stock price to reach $14.00 in the next year. View Analyst Ratings for SciClone Pharmaceuticals.

Who are some of SciClone Pharmaceuticals' key competitors?

Who are SciClone Pharmaceuticals' key executives?

SciClone Pharmaceuticals' management team includes the folowing people:

  • Jon S Saxe, Independent Chairman of the Board
  • Friedhelm Blobel Ph.D., President, Chief Executive Officer, Director
  • Wilson W. Cheung, Chief Financial Officer, Senior Vice President - Finance, Secretary
  • Hong Zhao, Chief Executive Officer - China Operations
  • Raymond Anthony Low CPA, Vice President - Finance, Controller
  • Lan Xie CPA, Vice President - Finance, China Chief Financial Officer
  • Nancy T. Chang Ph.D., Independent Director
  • Richard James Hawkins, Independent Director
  • Anthony Gregg Lapointe, Independent Director
  • Simon Li, Independent Director

How do I buy SciClone Pharmaceuticals stock?

Shares of SciClone Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is SciClone Pharmaceuticals' stock price today?

One share of SciClone Pharmaceuticals stock can currently be purchased for approximately $11.15.

How big of a company is SciClone Pharmaceuticals?

SciClone Pharmaceuticals has a market capitalization of $581.94 million. SciClone Pharmaceuticals employs 570 workers across the globe.

How can I contact SciClone Pharmaceuticals?

SciClone Pharmaceuticals' mailing address is 950 Tower Ln Ste 900, FOSTER CITY, CA 94404-2125, United States. The specialty pharmaceutical company can be reached via phone at +1-650-3583456.


MarketBeat Community Rating for SciClone Pharmaceuticals (SCLN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  133 (Vote Outperform)
Underperform Votes:  98 (Vote Underperform)
Total Votes:  231
MarketBeat's community ratings are surveys of what our community members think about SciClone Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

SciClone Pharmaceuticals (NASDAQ:SCLN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $14.00$14.00$14.00$14.00
Price Target Upside: 38.61% upside38.61% upside38.61% upside38.61% upside

SciClone Pharmaceuticals (NASDAQ:SCLN) Consensus Price Target History

Price Target History for SciClone Pharmaceuticals (NASDAQ:SCLN)

SciClone Pharmaceuticals (NASDAQ:SCLN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/8/2017Maxim GroupReiterated RatingBuy -> HoldLowView Rating Details
(Data available from 2/25/2016 forward)

Earnings

SciClone Pharmaceuticals (NASDAQ:SCLN) Earnings History and Estimates Chart

Earnings by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

SciClone Pharmaceuticals (NASDAQ SCLN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017Q2 2017$0.24$0.26$44.52 millionViewN/AView Earnings Details
5/10/2017Q1 2017$0.29$42.89 millionViewN/AView Earnings Details
3/6/2017Q4 2016$0.15$0.12$44.06 millionViewListenView Earnings Details
11/9/2016Q3 2016$0.19$40.54 millionViewN/AView Earnings Details
8/9/2016Q2 2016$0.18$38.99 millionViewN/AView Earnings Details
5/10/2016Q116$0.19$33.60 million$36.50 millionViewListenView Earnings Details
3/10/2016Q415$0.30$41.10 million$42.90 millionViewListenView Earnings Details
11/9/2015Q315$0.12$0.26$40.61 million$42.90 millionViewN/AView Earnings Details
8/10/2015Q215$0.12$0.26$37.27 million$37.90 millionViewListenView Earnings Details
5/11/2015Q414$0.03$0.17$34.00 million$33.60 millionViewListenView Earnings Details
3/11/2015Q4$0.15$0.29$38.93 million$41.43 millionViewN/AView Earnings Details
11/10/2014Q314$0.12$0.17$34.90 million$34.30 millionViewN/AView Earnings Details
8/11/2014Q214$0.10$0.20$33.40 million$32.50 millionViewListenView Earnings Details
5/12/2014Q114$0.08$0.10$32.20 million$26.60 millionViewListenView Earnings Details
3/12/2014Q314$0.15$0.08$38.30 million$32.70 millionViewListenView Earnings Details
11/12/2013Q114$0.15$0.18$39.70 million$35.20 millionViewListenView Earnings Details
8/7/2013Q2 2013$0.11$0.09$33.30 million$29.81 millionViewListenView Earnings Details
4/1/2013Q4 2012$0.12$0.04$35.30 million$33.10 millionViewListenView Earnings Details
11/9/2012Q312$0.21$0.20$43.09 million$40.70 millionViewN/AView Earnings Details
8/8/2012$0.18$0.20ViewN/AView Earnings Details
5/9/2012$0.11$0.15ViewN/AView Earnings Details
3/13/2012Q4 2011$0.14$0.19ViewN/AView Earnings Details
11/8/2011Q3 2011$0.14$0.15ViewN/AView Earnings Details
8/9/2011Q2 2011$0.10$0.12ViewN/AView Earnings Details
5/10/2011Q1 2011$0.10$0.08ViewN/AView Earnings Details
3/31/2011Q4 2010$0.11$0.08ViewN/AView Earnings Details
11/8/2010Q3 2010$0.10$0.16ViewN/AView Earnings Details
8/9/2010Q2 2010$0.08$0.11ViewN/AView Earnings Details
5/6/2010Q1 2010$0.07$0.09ViewN/AView Earnings Details
3/2/2010Q4 2009$0.01$0.05ViewN/AView Earnings Details
11/9/2009Q3 2009($0.01)$0.04ViewN/AView Earnings Details
8/4/2009Q2 2009$0.02$0.16ViewN/AView Earnings Details
3/3/2009Q4 2008($0.01)($0.07)ViewN/AView Earnings Details
11/6/2008Q3 2008($0.02)$0.02ViewN/AView Earnings Details
7/29/2008Q2 2008($0.01)ViewN/AView Earnings Details
5/8/2008Q1 2008($0.12)($0.12)ViewN/AView Earnings Details
3/13/2008Q4 2007($0.07)($0.08)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

SciClone Pharmaceuticals (NASDAQ:SCLN) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for SciClone Pharmaceuticals (NASDAQ:SCLN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

SciClone Pharmaceuticals (NASDAQ SCLN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.16%
Institutional Ownership Percentage: 72.80%
Insider Trades by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)
Institutional Ownership by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

SciClone Pharmaceuticals (NASDAQ SCLN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/16/2017Hong ZhaoCEOSell30,000$11.00$330,000.0030,000View SEC Filing  
8/16/2017Lan XieVPSell10,000$11.00$110,000.0010,000View SEC Filing  
6/30/2017Friedhelm BlobelCEOSell35,044$11.00$385,484.00149,863View SEC Filing  
6/20/2017Friedhelm BlobelCEOSell70,000$10.91$763,700.00152,209View SEC Filing  
6/12/2017Wilson Wai-Shun CheungCFOSell40,500$10.75$435,375.0014,372View SEC Filing  
6/8/2017Friedhelm BlobelCEOSell39,656$10.52$417,181.12112,999View SEC Filing  
6/6/2017Friedhelm BlobelCEOSell10,300$10.00$103,000.00View SEC Filing  
5/24/2017Friedhelm BlobelCEOSell21,464$9.32$200,044.48107,692View SEC Filing  
5/22/2017Friedhelm BlobelCEOSell18,536$9.44$174,979.84111,062View SEC Filing  
5/11/2017Friedhelm BlobelCEOSell18,226$10.00$182,260.00110,752View SEC Filing  
4/28/2017Friedhelm BlobelCEOSell4,400$10.01$44,044.0093,926View SEC Filing  
4/24/2017Friedhelm BlobelCEOSell40,000$9.56$382,400.00104,204View SEC Filing  
3/22/2017Friedhelm BlobelCEOSell40,000$9.47$378,800.00122,864View SEC Filing  
3/16/2017Lan XieVPSell1,000$9.60$9,600.001,000View SEC Filing  
3/6/2017Friedhelm BlobelCEOSell3,087$10.30$31,796.1090,613View SEC Filing  
3/3/2017Friedhelm BlobelCEOSell26,913$10.01$269,399.13View SEC Filing  
2/24/2017Friedhelm BlobelCEOSell823$9.71$7,991.3387,607View SEC Filing  
2/23/2017Friedhelm BlobelCEOSell39,177$9.83$385,109.91106,960View SEC Filing  
1/25/2017Friedhelm BlobelCEOSell8,868$10.54$93,468.7295,652View SEC Filing  
1/24/2017Friedhelm BlobelCEOSell61,132$10.44$638,218.0899,184View SEC Filing  
1/5/2017Friedhelm BlobelCEOSell9,600$11.02$105,792.0087,084View SEC Filing  
12/22/2016Friedhelm BlobelCEOSell70,000$10.55$738,500.00109,883View SEC Filing  
11/22/2016Friedhelm BlobelCEOSell70,000$10.22$715,400.00102,637View SEC Filing  
11/14/2016Friedhelm BlobelCEOSell30,000$10.27$308,100.00View SEC Filing  
10/27/2016Friedhelm BlobelCEOSell40,000$9.30$372,000.00126,784View SEC Filing  
10/26/2016Wilson Wai-Shun CheungCFOSell149,962$10.00$1,499,620.0015,064View SEC Filing  
10/17/2016Wilson Wai-Shun CheungCFOSell1,475$10.00$14,750.0016,609View SEC Filing  
8/30/2016Nancy T ChangDirectorSell25,040$10.30$257,912.0029,019View SEC Filing  
8/29/2016Wilson Wai-Shun CheungCFOSell1,872$10.35$19,375.2015,604View SEC Filing  
8/17/2016Friedhelm BlobelCEOSell501,875$10.00$5,018,750.00588,255View SEC Filing  
8/16/2016Wilson Wai-Shun CheungCFOSell7,802$10.62$82,857.2425,000View SEC Filing  
3/28/2016Friedhelm BlobelCEOSell10,000$9.29$92,900.00206,092View SEC Filing  
3/18/2016Friedhelm BlobelCEOSell10,000$9.09$90,900.00215,252View SEC Filing  
3/7/2016Friedhelm BlobelCEOSell20,000$10.01$200,200.00222,846View SEC Filing  
2/26/2016Friedhelm BlobelCEOSell10,000$9.98$99,800.00214,252View SEC Filing  
1/4/2016Friedhelm BlobelCEOSell200$9.01$1,802.00204,252View SEC Filing  
12/28/2015Friedhelm BlobelCEOSell10,000$9.17$91,700.00204,252View SEC Filing  
12/17/2015Friedhelm BlobelCEOSell9,400$9.00$84,600.00202,273View SEC Filing  
12/11/2015Friedhelm BlobelCEOSell600$9.00$5,400.00202,273View SEC Filing  
12/4/2015Friedhelm BlobelCEOSell10,000$9.22$92,200.00202,273View SEC Filing  
12/3/2015Lan XieCFOSell14,166$9.50$134,577.00View SEC Filing  
11/27/2015Friedhelm BlobelCEOSell10,000$9.24$92,400.00202,273View SEC Filing  
11/10/2015Wilson Wai-Shun CheungCFOSell7,803$9.51$74,206.53View SEC Filing  
7/24/2015Friedhelm BlobelCEOSell10,000$9.68$96,800.00View SEC Filing  
7/17/2015Friedhelm BlobelCEOSell10,000$9.72$97,200.00View SEC Filing  
7/10/2015Friedhelm BlobelCEOSell10,000$9.21$92,100.00View SEC Filing  
7/6/2015Friedhelm BlobelCEOSell20,000$10.80$216,000.00View SEC Filing  
6/26/2015Friedhelm BlobelCEOSell10,000$9.29$92,900.00View SEC Filing  
6/19/2015Friedhelm BlobelCEOSell10,000$9.42$94,200.00View SEC Filing  
6/12/2015Chuncai MengVPSell3,007$9.23$27,754.61View SEC Filing  
6/12/2015Friedhelm BlobelCEOSell10,000$9.13$91,300.00View SEC Filing  
6/8/2015Hong ZhaoCEOSell10,000$9.23$92,300.00View SEC Filing  
6/5/2015Friedhelm BlobelCEOSell10,000$9.07$90,700.00View SEC Filing  
6/1/2015Richard J HawkinsDirectorSell4,570$9.27$42,363.90View SEC Filing  
5/29/2015Friedhelm BlobelCEOSell10,000$9.38$93,800.00View SEC Filing  
5/29/2015Richard J HawkinsDirectorSell10,430$9.32$97,207.60View SEC Filing  
5/26/2015Richard J HawkinsDirectorSell11,982$9.44$113,110.08View SEC Filing  
5/22/2015Friedhelm BlobelCEOSell10,000$9.40$94,000.00View SEC Filing  
5/18/2015Chuncai MengVPSell23,660$9.56$226,189.60View SEC Filing  
5/15/2015Lan XieCFOSell26,668$9.20$245,345.60View SEC Filing  
4/24/2015Friedhelm BlobelCEOSell10,000$9.07$90,700.00View SEC Filing  
4/10/2015Friedhelm BlobelCEOSell10,000$9.10$91,000.00View SEC Filing  
3/12/2015Wilson Wai-Shun CheungCFOSell7,803$9.07$70,773.21View SEC Filing  
12/11/2014Richard J HawkinsDirectorSell15,591$8.80$137,200.80View SEC Filing  
9/2/2014Lan XieCFOSell36,468$6.97$254,181.96View SEC Filing  
8/15/2014Nancy T ChangDirectorBuy25,040$6.00$150,240.00View SEC Filing  
5/16/2014Hong ZhaoCEOSell12,500$4.75$59,375.00View SEC Filing  
8/22/2013Min YinVPSell10,938$5.50$60,159.00View SEC Filing  
8/20/2013Min YinVPSell12,500$5.50$68,750.00View SEC Filing  
2/28/2013Friedhelm BlobelCEOBuy3,000$3.86$11,580.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

SciClone Pharmaceuticals (NASDAQ SCLN) News Headlines

Source:
DateHeadline
SciClone Pharmaceuticals (SCLN) & CoLucid Pharmaceuticals (CLCD) Financial ContrastSciClone Pharmaceuticals (SCLN) & CoLucid Pharmaceuticals (CLCD) Financial Contrast
www.americanbankingnews.com - February 21 at 12:12 PM
Head-To-Head Survey: SciClone Pharmaceuticals (SCLN) versus Teligent (TLGT)Head-To-Head Survey: SciClone Pharmaceuticals (SCLN) versus Teligent (TLGT)
www.americanbankingnews.com - February 19 at 8:02 AM
Critical Review: Horizon Pharma (HZNP) versus SciClone Pharmaceuticals (SCLN)Critical Review: Horizon Pharma (HZNP) versus SciClone Pharmaceuticals (SCLN)
www.americanbankingnews.com - December 17 at 11:32 AM
Analyzing SciClone Pharmaceuticals (SCLN) and Bristol-Myers Squibb (BMY)Analyzing SciClone Pharmaceuticals (SCLN) and Bristol-Myers Squibb (BMY)
www.americanbankingnews.com - December 6 at 11:20 AM
Financial Comparison: SciClone Pharmaceuticals (SCLN) & The CompetitionFinancial Comparison: SciClone Pharmaceuticals (SCLN) & The Competition
www.americanbankingnews.com - November 2 at 3:08 AM
SciClone Pharmaceuticals, Inc. (SCLN) to Release Earnings on TuesdaySciClone Pharmaceuticals, Inc. (SCLN) to Release Earnings on Tuesday
www.americanbankingnews.com - October 31 at 9:26 AM
Technical Snapshots for These Drug Makers Stocks -- SciClone Pharma, Synergy Pharma, Novo Nordisk, and United TherapeuticsTechnical Snapshots for These Drug Makers Stocks -- SciClone Pharma, Synergy Pharma, Novo Nordisk, and United Therapeutics
www.bizjournals.com - October 17 at 3:41 PM
[$$] Investor Group Buys SciClone Pharmaceuticals[$$] Investor Group Buys SciClone Pharmaceuticals
finance.yahoo.com - October 14 at 7:42 AM
Impax Laboratories (IPXL) and SciClone Pharmaceuticals (SCLN) Head to Head ReviewImpax Laboratories (IPXL) and SciClone Pharmaceuticals (SCLN) Head to Head Review
www.americanbankingnews.com - October 13 at 2:26 AM
Analyzing SciClone Pharmaceuticals (SCLN) and Its CompetitorsAnalyzing SciClone Pharmaceuticals (SCLN) and Its Competitors
www.americanbankingnews.com - October 12 at 8:08 PM
NMI Holdings (NMIH) and Axcelis Technologies (ACLS) Set to Join S&P SmallCap 600NMI Holdings (NMIH) and Axcelis Technologies (ACLS) Set to Join S&P SmallCap 600
www.streetinsider.com - October 12 at 3:54 PM
SciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SCLN-US : October 11, 2017SciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SCLN-US : October 11, 2017
finance.yahoo.com - October 12 at 9:18 AM
Innocoll Holdings PLC (INNL) and SciClone Pharmaceuticals (SCLN) Head to Head ComparisonInnocoll Holdings PLC (INNL) and SciClone Pharmaceuticals (SCLN) Head to Head Comparison
www.americanbankingnews.com - October 10 at 12:12 PM
ETFs with exposure to SciClone Pharmaceuticals, Inc. : October 9, 2017ETFs with exposure to SciClone Pharmaceuticals, Inc. : October 9, 2017
finance.yahoo.com - October 10 at 6:39 AM
SciClone Pharmaceuticals, Inc. :SCLN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 27, 2017SciClone Pharmaceuticals, Inc. :SCLN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 27, 2017
finance.yahoo.com - October 3 at 12:11 PM
ETFs with exposure to SciClone Pharmaceuticals, Inc. : September 28, 2017ETFs with exposure to SciClone Pharmaceuticals, Inc. : September 28, 2017
finance.yahoo.com - October 3 at 12:11 PM
SciClone Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SCLN) : September 15, 2017SciClone Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SCLN) : September 15, 2017
finance.yahoo.com - September 15 at 8:34 AM
SciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCLN-US : September 13, 2017SciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCLN-US : September 13, 2017
finance.yahoo.com - September 14 at 9:46 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of SciClone Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 30, 2017SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of SciClone Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 30, 2017
finance.yahoo.com - August 30 at 9:00 AM
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of SciClone Pharmaceuticals, Inc. - SCLNSHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of SciClone Pharmaceuticals, Inc. - SCLN
finance.yahoo.com - August 17 at 9:27 PM
Lan Xie Sells 10,000 Shares of SciClone Pharmaceuticals, Inc. (SCLN) StockLan Xie Sells 10,000 Shares of SciClone Pharmaceuticals, Inc. (SCLN) Stock
www.americanbankingnews.com - August 16 at 10:44 PM
Hong Zhao Sells 30,000 Shares of SciClone Pharmaceuticals, Inc. (SCLN) StockHong Zhao Sells 30,000 Shares of SciClone Pharmaceuticals, Inc. (SCLN) Stock
www.americanbankingnews.com - August 16 at 10:26 PM
SciClone Announces End Of Go-Shop Period With No Parties Designated As Excluded PartiesSciClone Announces End Of Go-Shop Period With No Parties Designated As Excluded Parties
finance.yahoo.com - August 11 at 8:19 AM
SciClone Pharmaceuticals, Inc. (SCLN) Releases Quarterly  Earnings Results, Beats Estimates By $0.02 EPSSciClone Pharmaceuticals, Inc. (SCLN) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - August 10 at 8:40 PM
SciClone Reports Second Quarter 2017 Financial ResultsSciClone Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 10 at 7:40 AM
SciClone posts 2Q profitSciClone posts 2Q profit
finance.yahoo.com - August 10 at 7:40 AM
ETFs with exposure to SciClone Pharmaceuticals, Inc. : August 4, 2017ETFs with exposure to SciClone Pharmaceuticals, Inc. : August 4, 2017
finance.yahoo.com - August 4 at 7:59 AM
Insider Selling: SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) CEO Sells 35,044 Shares of StockInsider Selling: SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) CEO Sells 35,044 Shares of Stock
www.americanbankingnews.com - July 3 at 4:35 PM
SciClone Pharmaceuticals, Inc. (SCLN) Sees Large Decrease in Short InterestSciClone Pharmaceuticals, Inc. (SCLN) Sees Large Decrease in Short Interest
www.americanbankingnews.com - July 1 at 7:06 AM
INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of SciClone Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm for Additional ...INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of SciClone Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm for Additional ...
www.businesswire.com - June 20 at 6:37 AM
SciClone Pharmaceuticals Inc (SCLN.OQ)SciClone Pharmaceuticals Inc (SCLN.OQ)
www.reuters.com - June 16 at 2:08 AM
WeissLaw LLP: The Proposed Acquisition of SciClone Pharmaceuticals Inc. May Not Be In the Best Interest of SCLN ShareholdersWeissLaw LLP: The Proposed Acquisition of SciClone Pharmaceuticals Inc. May Not Be In the Best Interest of SCLN Shareholders
www.bizjournals.com - June 14 at 12:47 AM
SciClone to be Bought by China-Based GroupSciClone to be Bought by China-Based Group
www.baystreet.ca - June 8 at 9:53 PM
SciClone Announces Merger; Consortium To Acquire SciClone For $11.18/shrSciClone Announces Merger; Consortium To Acquire SciClone For $11.18/shr
www.nasdaq.com - June 8 at 9:53 PM
Sciclone Pharma (SCLN) Agrees to be Acquired by Consortium Led By GL Capital for $11.18/ShareSciclone Pharma (SCLN) Agrees to be Acquired by Consortium Led By GL Capital for $11.18/Share
www.streetinsider.com - June 8 at 9:53 PM
SciClone To Present At Needham Healthcare...SciClone To Present At Needham Healthcare...
www.benzinga.com - March 27 at 9:17 AM
SciClone Pharmaceuticals (SCLN) CEO Friedhelm Blobel on Q4 2016 Results - Earnings Call Transcript - Seeking AlphaSciClone Pharmaceuticals' (SCLN) CEO Friedhelm Blobel on Q4 2016 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 7 at 7:35 PM
SciClone Reports 2016 Financial Results And 2017 OutlookSciClone Reports 2016 Financial Results And 2017 Outlook
us.rd.yahoo.com - March 6 at 11:38 AM
Q4 2016 SciClone Pharmaceuticals Inc Earnings Release - Before Market OpenQ4 2016 SciClone Pharmaceuticals Inc Earnings Release - Before Market Open
biz.yahoo.com - March 6 at 11:38 AM
SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementsSCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
biz.yahoo.com - March 6 at 11:38 AM
SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, FinSCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Fin
biz.yahoo.com - February 28 at 7:21 PM
SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal OfficersSCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - January 6 at 9:50 PM

SEC Filings

SciClone Pharmaceuticals (NASDAQ:SCLN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

SciClone Pharmaceuticals (NASDAQ:SCLN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

SciClone Pharmaceuticals (NASDAQ SCLN) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.